Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Dezember 2017 10:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD)

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
09. November 2017 08:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
07. November 2017 08:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics to Participate in Four Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
01. November 2017 09:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers

Updated ATA230 results in patients with cytomegalovirus (CMV) viremia and disease post-transplant will also be presented SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Atara...
26. Oktober 2017 08:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
25. Oktober 2017 08:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190

Three patients in the study improved their Expanded Disability Status Scale (EDSS) score Reduction in fatigue was a consistent observation in responding patients, as highlighted in a presentation at...
19. Oktober 2017 08:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)

Enrollment to begin in Australia; U.S. sites expected to open in early 2018 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading...
16. Oktober 2017 08:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS)

Five of eight progressive MS patients who received the full course of autologous ATA190 experienced clinical improvements Further results for all 10 patients in the ongoing Phase 1 study will be...
11. September 2017 08:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129

Health Canada New Drug Submission (NDS) planned based on Phase 1 and 2 clinical results and supported by available data from anticipated MATCH and ALLELE Phase 3 studies, which are expected to be...
05. September 2017 08:00 ET | Quelle: Atara Biotherapeutics, Inc.

Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for...

Vorherige Seite

Nächste Seite